公开(公告)号：WO1998006822A1

公开(公告)日：1998-02-19

申请号：PCT/JP1997002749

申请日：1997-08-06

Applicant: THE GREEN CROSS CORPORATION ,  AMATSUJI, Yasuo ,  TAMASHIMA, Hiroshi ,  KOBAYASHI, Kaoru ,  OHMURA, Takao

Inventor： THE GREEN CROSS CORPORATION

IPC: C12N05/02

CPC classification number: C12N5/0037 ,  C12N2500/25 ,  C12N2500/84

Abstract: A culture medium containing human serum albumin obtained by genetic manipulations (rHSA); a method for culturing animal cells characterized by culturing the cells in the above-mentioned medium; and a process for producing a physiologically active substance characterized by culturing animal cells capable of producing the physiologically active substance in the above-mentioned medium and taking up the produced physiologically active substance from the culture. The use of rHSA with uniform qualities makes it possible to achieve the proliferation of the cells and the productivity of the physiologically active substance each comparable to those achieved by using a serum-containing medium and/or a conventional serum-free medium containing HSA originating in plasma while stabilizing the medium qualities and ensuring the reproducibility of the culture.

Abstract translation: 通过遗传操作（rHSA）获得含有人血清白蛋白的培养基; 用于培养以上述培养基培养细胞为特征的动物细胞的方法; 以及生产生物活性物质的方法，其特征在于培养能够在上述培养基中生产生理活性物质的动物细胞，并从培养物中吸收生成的生理活性物质。 使用具有均匀质量的rHSA使得可以实现细胞的增殖和生理活性物质的生产力，其与通过使用含有血清的培养基和/或含有HSA的常规无血清培养基（其源自于 同时稳定培养基质量并确保培养物的再现性。

公开(公告)号：WO1998000521A1

公开(公告)日：1998-01-08

申请号：PCT/JP1997002167

申请日：1997-06-23

Applicant: THE GREEN CROSS CORPORATION ,  AMATSUJI, Yasuo ,  TAMASHIMA, Hiroshi ,  UEMURA, Yahiro

Inventor： THE GREEN CROSS CORPORATION

IPC: C12N05/00

CPC classification number: C12N5/0037

Abstract: Serum-free media characterized by containing insulin and peptone but being substantially free from albumin and transferrin; a method for culturing animal cells characterized by culturing the cells in the above-mentioned media; and a process for producing physiologically active substances characterized by culturing animal cells capable of producing the substances in the above-mentioned media and recovering the substances thus produced from the cultures. These serum-free media allow sufficient proliferation of cells, facilitate the recovery of the physiologically active substances from the cultures, and are scarcely contaminated, thus enabling the provision of the above-mentioned culture method and production process.

Abstract translation: 无血清培养基，其特征在于含有胰岛素和蛋白胨，但基本上不含白蛋白和转铁蛋白; 用于培养以上述培养基培养细胞为特征的动物细胞的方法; 以及生产生理活性物质的方法，其特征在于培养能够在上述培养基中产生物质的动物细胞，并从培养物中回收由此产生的物质。 这些无血清培养基允许细胞的充分增殖，促进培养物中生理活性物质的回收，几乎不被污染，从而能够提供上述培养方法和生产方法。

公开(公告)号：WO1997029128A1

公开(公告)日：1997-08-14

申请号：PCT/JP1997000284

申请日：1997-02-06

Applicant: THE GREEN CROSS CORPORATION ,  MATSUDA, Hiroshi ,  KAMIDE, Kaeko ,  AMATSUJI, Yasuo ,  IMAGAWA, Takashi ,  IKEDA, Yasuo ,  MURATA, Mitsuru

Inventor： THE GREEN CROSS CORPORATION

IPC: C07K14/705

CPC classification number: A61K9/1271 ,  A61K38/00 ,  A61K47/62 ,  A61K47/6911 ,  C07K14/705 ,  C07K14/70596

Abstract: A complex comprising GPIb and a lipid having a functional group. As it can bind with vWF and can form aggregates, it is useful as a platelet substitute, medicines for preventing and curing vascular lesion, vascular injury and thrombosis, a diagnostic agent for vWF deficiency, biological-medical reagents, and reagents for screening platelet aggregation inhibitors and antithrombotic agents. Also, as it is apt to specifically concentrate around the lesioned vascular parts, it is useful as diagnostic agents for testing vascular lesion, injured parts and thrombosed parts or remedies therefor.

Abstract translation: 包含GPIb和具有官能团的脂质的复合物。 由于它可以与vWF结合并且可以形成聚集体，它可用作血小板替代物，用于预防和治疗血管损伤，血管损伤和血栓形成的药物，用于vWF缺陷的诊断剂，生物医学试剂和用于筛选血小板聚集的试剂 抑制剂和抗血栓形成剂。 此外，由于易于特异性地集中在损伤的血管部分周围，因此它可用作测试血管损伤，受伤部件和血栓部位的诊断剂或其补救措施。

公开(公告)号：WO1996009839A1

公开(公告)日：1996-04-04

申请号：PCT/JP1995001979

申请日：1995-09-28

Applicant: THE GREEN CROSS CORPORATION ,  TAKAHASHI, Tuyoshi ,  MIYANO, Kenmi ,  NISHIMAKI, Hideo ,  IRIE, Koichi ,  SAKI, Toshiyuki ,  TOMIOKA, Shinji

Inventor： THE GREEN CROSS CORPORATION

IPC: A61K39/395

CPC classification number: C07K16/00

Abstract: A more safe immunoglobulin preparation, especially one used for intramuscular injection, that can be obtained by an efficient and well-operable production process without causing viral contamination. The preparation is HCV genome negative, contains HCV genome in a concentration of at most 1 PCR unit/ml in a 0.1-15 w/v % immunoglobulin solution, and has a HCV genome removal rate of 10 or above.

Abstract translation: 更安全的免疫球蛋白制剂，特别是用于肌内注射的免疫球蛋白制剂，其可以通过有效且良好可操作的生产方法获得而不引起病毒污染。 该制备物为HCV基因组阴性，含0.1至15w / v％免疫球蛋白溶液中至多1个PCR单位/ ml浓度的HCV基因组，HCV基因组去除率为10 3或更高。

公开(公告)号：WO1995019789A1

公开(公告)日：1995-07-27

申请号：PCT/JP1995000057

申请日：1995-01-20

Applicant: THE GREEN CROSS CORPORATION ,  OKAJIMA, Kenji ,  TAOKA, Yuji

Inventor： THE GREEN CROSS CORPORATION

IPC: A61K38/57

CPC classification number: A61K38/57

Abstract: A motor-function disorder preventive or remedy, tissue trouble preventive or remedy, spinal ischemia preventive or remedy, and spinal injury preventive or remedy, each containing a human-origin antithrombin III as the active ingredient. The antithrombin III has the activity of ameliorating mammalian tissue troubles and motor-function disorders, especially those caused by spinal ischemia or spinal injury, for example, paralysis.

Abstract translation: 运动功能障碍预防或治疗，组织麻醉预防或治疗，脊髓缺血预防或治疗，以及脊髓损伤预防或治疗，每个含有人源抗凝血酶III作为活性成分。 抗凝血酶III具有改善哺乳动物组织麻烦和运动功能障碍，特别是由脊髓缺血或脊髓损伤引起的功能障碍，例如麻痹的活性。

公开(公告)号：WO1995017819A1

公开(公告)日：1995-07-06

申请号：PCT/JP1994002299

申请日：1994-12-28

Applicant: RENGO CO., LTD. ,  THE GREEN CROSS CORPORATION ,  FUJITA, Masao ,  KAMEI, Kiyoshi ,  KAWAZU, Kiyoko ,  HIROHAMA, Shuji ,  MIZUKAMI, Yuichi ,  SEKIYAMA, Yasushi ,  TAKATA, Asami ,  NUMATA, Shoko

Inventor： RENGO CO., LTD. ,  THE GREEN CROSS CORPORATION

IPC: A01N47/48

CPC classification number: A01N47/46 ,  A01N63/00 ,  A01N25/34 ,  A01N25/12 ,  A01N25/18 ,  A01N2300/00

Abstract: A controlled-release AIT (allyl isothiocyanate) preparation comprising AIT and shellac serving as a barrier against AIT release; the above preparation comprising a shellac containing AIT incorporated therein (an AIT-incorporating shellac); the above preparation wherein the AIT-incorporating shellac is in the form of plate, block or granule; the above preparation wherein the AIT-incorporating shellac has been adhered onto or mixed into a base material; the above preparation wherein the base material is one selected from among plastic plate, paper, non-woven fabric and woven fabric; and the above preparation wherein the AIT of the AIT-incorporating shellac is supported on a carrier. The AIT vapor release rate can be varied by appropriately selecting the chemical composition, preparation process and so forth of the AIT-incorporating shellac. Sustained release of AIT vapor for long is also possible. As the AIT-incorporating shellac can be easily worked into various forms, the AIT preparation can be provided in various forms. It is useful in various fields of food, packaging material, construction material and so forth as a functional material which is highly stable and has antimicrobial, antimold, freshness-retaining and insectproof properties.

Abstract translation: AIT（烯丙基异硫氰酸烯丙酯）制剂，其包含AIT和虫胶作为AIT释放的屏障; 包含含有AIT的紫胶的上述制剂（掺有AIT的紫胶）; 上述制剂，其中含有AIT的紫胶是板，块或颗粒的形式; 上述制备其中掺入了AIT的紫胶已经粘附到基质上或混合到基材中; 上述制剂，其中基材是选自塑料板，纸，无纺布和机织织物中的一种; 以及其中载有AIT的紫胶的AIT负载在载体上的制备。 AIT蒸汽释放速率可以通过适当选择掺入AIT的虫胶的化学成分，制备过程等来改变。 长时间持续释放AIT蒸气也是可能的。 由于加入AIT的紫胶可以容易地加工成各种形式，因此可以以各种形式提供AIT制剂。 在食品，包装材料，建筑材料等的各个领域中，作为高度稳定且具有抗菌，防霉，保鲜和防虫性能的功能材料是有用的。

公开(公告)号：WO1994022875A1

公开(公告)日：1994-10-13

申请号：PCT/JP1994000508

申请日：1994-03-29

Applicant: THE GREEN CROSS CORPORATION ,  SENJU PHARMACEUTICAL CO., LTD. ,  HOSONO, Hiroshi ,  AOTSUKA, Tomoji ,  NAKAMURA, Yoshiyuki ,  MATSUI, Tetsuo ,  ISHIKAWA, Hiromichi

Inventor： THE GREEN CROSS CORPORATION ,  SENJU PHARMACEUTICAL CO., LTD.

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: A pyridothiazineacetic acid compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, a process for producing the same, and a pharmaceutical composition, an aldose reductase inhibitor and a preventive and therapeutic agent for the complications of diabetes, wherein each symbol is as defined in the specification. The compound and pharmaceutically acceptable salts thereof have an aldose reductase inhibitor activity and an excellent stability, and hence they are useful as preventive and therapeutic agents for the complications of diabetes, such as faulty union of injured cornea, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis. The invention process serves to produce the above compound efficiently.

Abstract translation: 由通式（I）表示的吡啶并噻吩乙酸化合物或其药学上可接受的盐，其制备方法，药物组合物，醛糖还原酶抑制剂和糖尿病并发症的预防和治疗剂，其中每个符号是 如说明书中所定义。 该化合物及其药学上可接受的盐具有醛糖还原酶抑制剂活性和优异的稳定性，因此它们可用作糖尿病并发症的预防和治疗剂，例如受损的角膜错位，白内障，神经症，视网膜病变和肾病， 特别是白内障和神经症。 本发明方法有效地生产上述化合物。

公开(公告)号：WO1994022845A1

公开(公告)日：1994-10-13

申请号：PCT/JP1994000490

申请日：1994-03-25

Applicant: SENJU PHARMACEUTICAL CO., LTD. ,  THE GREEN CROSS CORPORATION ,  HASE, Takema ,  KUMONAKA, Takahiro ,  SHIMIZU, Chikako ,  HOSONO, Hiroshi ,  AOTSUKA, Tomoji ,  NAKAMURA, Yoshiyuki ,  MATSUI, Tetsuo ,  ISHIKAWA, Hiromichi

Inventor： SENJU PHARMACEUTICAL CO., LTD. ,  THE GREEN CROSS CORPORATION

IPC: C07D277/64

CPC classification number: C07C255/25 ,  C07D277/64

Abstract: A benzothiazole compound represented by general formula (I) and a pharmaceutically acceptable salt thereof wherein, R represents halogen; R and R represent each independently hydrogen or halogen; R represents hydrogen, halogen, lower alkyl, alkoxy or alkylmercapto; and R represents hydrogen or lower alkyl. The compound (I) and salt thereof have an aldose reductase inhibitor activity against mammals including human and is excellent in safety. Therefore they are useful as remedies for treating complications of diabetes, such as defective union of injured cornea, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis.

Abstract translation: 由通式（I）表示的苯并噻唑化合物及其药学上可接受的盐，其中R 1表示卤素; R 2和R 3各自独立地表示氢或卤素; R 4表示氢，卤素，低级烷基，烷氧基或烷基巯基; R 5表示氢或低级烷基。 化合物（I）及其盐具有对包括人类的哺乳动物的醛糖还原酶抑制剂活性，并且安全性优异。 因此，它们可用作治疗糖尿病并发症的补救措施，例如受损的角膜联合不良，白内障，神经症，视网膜病变和肾病，特别是白内障和神经症。

公开(公告)号：WO1994017058A1

公开(公告)日：1994-08-04

申请号：PCT/JP1993001822

申请日：1993-12-15

Applicant: THE GREEN CROSS CORPORATION ,  YANAI, Kzuhiko ,  WATANABE, Takehiko ,  GOTOH, Tomokazu ,  SAKASHITA, Hiroshi ,  MURAKAMI, Kazuki ,  SUGIURA, Masanori ,  FUKAYA, Chikara

Inventor： THE GREEN CROSS CORPORATION

IPC: C07D401/04

CPC classification number: C07D401/04

Abstract: The invention aims at providing a novel compound having vitamin H3 receptor antagonism and relates to a compound represented by general formula (O) or pharmaceutically acceptable salts thereof, wherein m represents an integer of 4 to 6; R1 represents hydrogen, lower alkyl or aralkyl; R2 and R3 may be the same or different from each other and each represents hydrogen or lower alkyl; R4 represents hydrogen, linear or branched alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted aryl, or optionally substituted aralkyl; Z represents R5 or A-R6; A represents S or O; R5 represents hydrogen, lower alkyl, optionally substituted aryl, or optionally substituted aralkyl; and R6 represents lower alkyl, lower alkenyl, lower alkynyl, or optionally substituted aralkyl.

Abstract translation: 本发明旨在提供一种具有维生素H3受体拮抗作用的新化合物，涉及由通式（O）表示的化合物或其药学上可接受的盐，其中m表示4至6的整数; R1代表氢，低级烷基或芳烷基; R2和R3可以相同或不同，各自代表氢或低级烷基; R 4表示氢，直链或支链烷基，环烷基，环烷基烷基，任选取代的芳基或任选取代的芳烷基; Z表示R5或A-R6; A表示S或O; R5表示氢，低级烷基，任选取代的芳基或任选取代的芳烷基; 并且R 6表示低级烷基，低级烯基，低级炔基或任选取代的芳烷基。

公开(公告)号：WO1994012499A1

公开(公告)日：1994-06-09

申请号：PCT/JP1992001575

申请日：1992-12-01

Applicant: THE GREEN CROSS CORPORATION ,  MATSUURA, Akihiro ,  ASHIZAWA, Naoki ,  HASE, Takema

Inventor： THE GREEN CROSS CORPORATION

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: A 1,8-naphthyridin-2-one derivative, a pharmaceutically acceptable acid addition salt thereof, and a remedy containing the same as an active ingredient for treating various diseases including peripheral diseases such as hypertension, renal failure, heart failure, angina pectoris, myocardial infarction and peripheral circulatory disturbance, diseases of circulatory and respiratory systems such as arteriosclerosis, obstructive thromboangiitis, aortitis syndrome and bronchial asthma, central nervous system diseases such as depression, hypofunction of central nervous system after cerebrovascular obstruction, cerebrovascular dementia, senile dementia, Alzheimer disease and disturbance of memory and learning functions, various inflammations, and obesity.

Abstract translation: 1,8-萘啶-2-酮衍生物，其药学上可接受的酸加成盐，以及含有其作为活性成分的治疗剂，用于治疗各种疾病，包括高血压，肾功能衰竭，心力衰竭，心绞痛， 心肌梗死和周围循环障碍，循环系统和呼吸系统疾病如动脉硬化，阻塞性血管炎，主动脉炎综合征和支气管哮喘，中枢神经系统疾病如抑郁症，脑血管阻塞后中枢神经系统功能低下，脑血管性痴呆，老年痴呆，阿尔茨海默病 疾病和记忆障碍和学习功能，各种炎症和肥胖。